Neowise Biotechnology

Suzhou, China · Founded 2020 · Privately Held (backing)

Developer of TCR-T (T-cell receptor-based therapy), an immune cell therapy designed for solid tumors. Neowise Biotechnology is based in Suzhou, China and was founded in 2020. Its last reported valuation was $229 million in Oct 2025. It has raised $57.1 million.

Last reported valuation

$229.1M

Oct 2026

Priced at

—

Total raised

$57.1M

Last round

—

How much has Neowise Biotechnology raised?

$57.1Macross 0 recorded rounds

Free account

More of Neowise Biotechnology with a free account

·The complete investor list: 15 names
·Watch Neowise Biotechnology: the Monday email on marks, rounds and moves

Create free account

No card required

Membership and data by Private Market View

Neowise Biotechnology investors

15 investors are on record for Neowise Biotechnology, including Suzhou Oriza Holdings Corporation, Baidu Ventures, Leader Venture Capital and Beijing Delian Yuntong Investment Management Company.

For fundraisers

Raising for a company like Neowise Biotechnology?

15 investors have backed Neowise Biotechnology.

See all 15 investors →

Frequently asked about Neowise Biotechnology

How much has Neowise Biotechnology raised?: Neowise Biotechnology has raised $57.1M in total across 0 recorded funding rounds.